港股新股中慧生物-B（02627）今日首次公开交易，盘中股价大涨158.76%，引发市场广泛关注。该股在早盘开市后即以33港元高开，较发行价12.9港元大幅上涨155.81%，截至发稿时成交额已达1.7亿港元。
中慧生物-B的强劲表现主要得益于其火爆的招股情况。公司此前公布的招股结果显示，香港公开发售部分获得了惊人的4007.64倍超额认购，冻结资金高达2100亿港元，成为今年以来以"18A规则"上市的生物科技股中的"超购王"。国际配售部分也获得0.99倍认购。公司最终以每股12.9港元的下限价格定价，共发行3344.26万股股份，募集资金净额约3.83亿港元。值得注意的是，多家全球知名长线基金，如VanCapital和InfiniCapital等，均积极参与认购，彰显了机构投资者对公司前景的信心。
作为一家专注于人用疫苗研发、制造及商业化的生物科技企业，中慧生物的核心产品颇具市场竞争力。公司的四价流感病毒亚单位疫苗（慧尔康欣®）是目前国内唯一获批的同类产品，可用于三岁及以上人群，每针投标价格为319元。此外，公司还有一款即将于今年第三季度启动III期临床试验的冻干人用狂犬病疫苗，以及包括重组带状疱疹疫苗、23价肺炎球菌多糖疫苗在内的11款在研产品管线，显示出强劲的研发实力和市场潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.